Molecular, Cell and Cancer Biology
First Thesis Advisor
Inflammation, cell death, RIPK1, TNF, shock, sepsis
Necroptosis, a type of regulated necrotic cell death, involves cell membrane permeabilization and has been implicated in various acute and chronic pro-inflammatory diseases, including ischemia-reperfusion injury and neurodegenerative diseases. By using in vitro reconstitution studies and a chemical inhibitor, the kinase activity of the serine/threonine kinase RIPK1 had been shown to regulate necroptotic signaling downstream of TNF and Toll-like receptors (TLRs). To investigate the contribution of RIPK1 kinase activity to inflammation and necroptosis in vivo, we generated kinase inactive RIPK1 knock-in mice. Utilizing fibroblasts and macrophages from these mice, we demonstrate that RIPK1 kinase activity is required for necroptotic complex formation and death induction downstream of TNFR1 and TLRs 3 and 4. We show that RIPK1 kinase inactive mice are resistant to TNF-induced shock and exhibit impaired upregulation of TNF-induced cytokines and chemokines in vitro and in vivo. By using bone marrow reconstitution experiments, we demonstrate that RIPK1 kinase activity in a non-hematopoietic lineage drives TNF-induced lethality. We establish that RIPK1 kinase activity is required for TNF-induced increases in intestinal and vascular permeability and clotting, and implicate endothelial cell necroptosis as an underlying factor contributing to TNF/zVAD-induced shock. Thus, work in this thesis reveals that RIPK1 kinase inhibitors may have promise in treating shock and sepsis.
Zelic, M. The Role of RIPK1 Kinase Activity in Regulating Inflammation and Necroptotic Death. (2018). University of Massachusetts Medical School. GSBS Dissertations and Theses. Paper 952. DOI: 10.13028/M2GQ3V. https://escholarship.umassmed.edu/gsbs_diss/952
Rights and Permissions
Licensed under a Creative Commons license
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Available for download on Thursday, January 31, 2019